Expert Review of Anticancer Therapy最新文献

Apalutamide in prostate cancer: clinical evidence, disease modification hypothesis, and emerging treatment de‑intensification strategies. 阿帕鲁胺在前列腺癌中的应用：临床证据、疾病改变假说和新出现的治疗强化策略

IF 3 3区医学

Expert Review of Anticancer Therapy Pub Date : 2026-10-15 DOI: 10.1080/14737140.2026.2749345

Martina Catalano, Giandomenico Roviello

{"title":"Apalutamide in prostate cancer: clinical evidence, disease modification hypothesis, and emerging treatment de‑intensification strategies.","authors":"Martina Catalano, Giandomenico Roviello","doi":"10.1080/14737140.2026.2749345","DOIUrl":"https://doi.org/10.1080/14737140.2026.2749345","url":null,"abstract":"Introduction: Apalutamide is a potent androgen receptor pathway inhibitor with established efficacy in non-metastatic castration-resistant and metastatic hormone-sensitive prostate cancer. Emerging evidence has also raised questions regarding the biological impact of early treatment, depth of response, and the potential for response-adapted treatment strategies.Areas covered: This narrative review summarizes randomized clinical trials and real-world evidence evaluating apalutamide across the prostate cancer continuum, with particular emphasis on efficacy, safety, PSA kinetics, comparative effectiveness, and treatment de-intensification. PubMed/MEDLINE and the Cochrane Library were searched from database inception through July 2026, supplemented by reference-list screening and relevant conference proceedings.Expert opinion: Apalutamide provides robust evidence of clinical benefit in established indications, while deep PSA responses represent an important prognostic marker that requires prospective validation before being used to guide treatment intensity. The concept of disease modification remains biologically plausible but unproven, and treatment de-intensification should currently be considered investigational. Future studies should integrate longitudinal response assessment, molecular biomarkers, imaging, patient-reported outcomes, and long-term clinical endpoints to identify patients who may safely benefit from treatment adaptation.","PeriodicalId":12099,"journal":{"name":"Expert Review of Anticancer Therapy","volume":" ","pages":"1-8"},"PeriodicalIF":3.0,"publicationDate":"2026-10-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149192206","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

How zongertinib was developed for HER2-mutant non-small cell lung cancer: a plain language summary. 如何开发宗厄替尼治疗her2突变的非小细胞肺癌：简单的语言总结。

IF 3 3区医学

Expert Review of Anticancer Therapy Pub Date : 2026-10-11 DOI: 10.1080/14737140.2026.2731196

John V Heymach, Birgit Wilding

引用次数: 0

Targeting KIT and PDGFRA mutations in advanced GIST: current and future clinical implications. 靶向KIT和PDGFRA突变在晚期gist：当前和未来的临床意义。

IF 3 3区医学

Expert Review of Anticancer Therapy Pub Date : 2026-10-11 DOI: 10.1080/14737140.2026.2746618

Alice Costa, Annalisa Astolfi, Livia Gozzellino, Maria Concetta Nigro, Maria Abbondanza Pantaleo, Margherita Nannini

{"title":"Targeting KIT and PDGFRA mutations in advanced GIST: current and future clinical implications.","authors":"Alice Costa, Annalisa Astolfi, Livia Gozzellino, Maria Concetta Nigro, Maria Abbondanza Pantaleo, Margherita Nannini","doi":"10.1080/14737140.2026.2746618","DOIUrl":"10.1080/14737140.2026.2746618","url":null,"abstract":"Introduction: Gastrointestinal stromal tumors (GISTs) are a paradigmatic example of precision oncology. Identification of KIT and PDGFRA mutations has enabled effective targeted therapies for advanced disease. Although these treatments have significantly improved patient survival, drug resistance remains a major clinical challenge.Areas covered: This narrative review examines advanced KIT/PDGFRA-mutant GIST, including established therapies, mechanisms of resistance, plasma molecular profiling, and emerging therapeutic approaches. Relevant English-language literature available in full text was identified through PubMed searches using terms related to GIST and primary and secondary mutations. Clinical findings are distinguished from exploratory biomarkers and preclinical evidence.Expert opinion: GISTs remain a paradigmatic example of precision oncology, demonstrating how the identification of oncogenic driver mutations can profoundly alter the natural history of a previously chemoresistant malignancy. Over the next five to ten years, we expect treatment pathways to become increasingly guided by genotype, supported by prospective evidence. While more effective kinase inhibition remains important, research should also explore therapeutic targets beyond kinase signaling, including tumor dependencies and interactions with the immune and stromal microenvironment. The clinical value of these approaches will ultimately depend on their ability to translate biological insights into longer survival while preserving quality of life and minimizing treatment burden.","PeriodicalId":12099,"journal":{"name":"Expert Review of Anticancer Therapy","volume":" ","pages":"1-11"},"PeriodicalIF":3.0,"publicationDate":"2026-10-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149147724","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Myelodysplastic syndromes/neoplasms presenting with isolated thrombocytopenia: a poorly understood pathophysiology, difficult to diagnose, and challenging to treat entity. 骨髓增生异常综合征/肿瘤表现为孤立的血小板减少：一个不太了解的病理生理学，难以诊断，并具有挑战性的治疗实体。

IF 3 3区医学

Expert Review of Anticancer Therapy Pub Date : 2026-10-08 DOI: 10.1080/14737140.2026.2746616

Shehab F Mohamed, Mohammed Abdulgayoom, Abdulrahman F Al-Mashdali, Rowan Mesilhy, Jan Philipp Bewersdorf, Amer M Zeidan

{"title":"Myelodysplastic syndromes/neoplasms presenting with isolated thrombocytopenia: a poorly understood pathophysiology, difficult to diagnose, and challenging to treat entity.","authors":"Shehab F Mohamed, Mohammed Abdulgayoom, Abdulrahman F Al-Mashdali, Rowan Mesilhy, Jan Philipp Bewersdorf, Amer M Zeidan","doi":"10.1080/14737140.2026.2746616","DOIUrl":"https://doi.org/10.1080/14737140.2026.2746616","url":null,"abstract":"Introduction: Myelodysplastic syndromes/neoplasms (MDS) usually present with anemia or multilineage cytopenias, whereas isolated thrombocytopenia is uncommon and may closely mimic immune thrombocytopenia (ITP). In lower-risk MDS (LR-MDS) without increased blasts, thrombocytopenia may be the sole or predominant abnormality, leading to diagnostic delay and unnecessary exposure to immune-directed therapies.Areas covered: A narrative literature search was undertaken using terms related to MDS, isolated thrombocytopenia, ITP, clonal cytopenia of undetermined significance (CCUS), del(20q), and treatment. This review examines the clinical phenotype, pathophysiology, diagnostic evaluation, prognosis, and management of MDS with isolated thrombocytopenia (MDS-IT), emphasizing differentiation from ITP and CCUS and the roles of marrow morphology, cytogenetics, molecular testing, and longitudinal assessment. Particular attention is given to isolated del(20q), which is often associated with platelet-predominant disease, low blast burden, and relatively indolent behavior, although coexisting mutations such as ASXL1, TP53, and spliceosome-gene alterations may worsen prognosis. Supportive care remains foundational; thrombopoietin receptor agonists provide the strongest prospective evidence in selected lower-risk patients, whereas evidence for hypomethylating agents remains indirect.Expert opinion: MDS-IT is a biologically heterogeneous clinical phenotype rather than a formal subtype. Accurate diagnosis and individualized management require integrated clinical, morphologic, cytogenetic, molecular, and bleeding-risk assessment.","PeriodicalId":12099,"journal":{"name":"Expert Review of Anticancer Therapy","volume":" ","pages":""},"PeriodicalIF":3.0,"publicationDate":"2026-10-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149135531","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Real-world clinical and economic outcomes in chemotherapy-naïve patients with metastatic castration-resistant prostate cancer. chemotherapy-naïve转移性去势抵抗性前列腺癌患者的临床和经济结果

IF 3 3区医学

Expert Review of Anticancer Therapy Pub Date : 2026-10-06 DOI: 10.1080/14737140.2026.2738626

Rana R McKay, Jennifer Nguyen, Barinder Kang, Clare Byrne, Jackson Tang, Kyle Runeckles, Amrita Sawhney, Jeetvan Patel

{"title":"Real-world clinical and economic outcomes in chemotherapy-naïve patients with metastatic castration-resistant prostate cancer.","authors":"Rana R McKay, Jennifer Nguyen, Barinder Kang, Clare Byrne, Jackson Tang, Kyle Runeckles, Amrita Sawhney, Jeetvan Patel","doi":"10.1080/14737140.2026.2738626","DOIUrl":"https://doi.org/10.1080/14737140.2026.2738626","url":null,"abstract":"Background: Real-world treatment and outcomes for patients with metastatic castration-resistant prostate cancer (mCRPC) are evolving.Research design and methods: This retrospective study used data from the US Surveillance, Epidemiology, and End Results-Medicare Database (01/01/2009-12/31/2019). Patients with mCRPC who previously received one androgen receptor pathway inhibitor (ARPI) followed by either a second ARPI (ARPI cohort) or a taxane (taxane cohort) were included. Treatment patterns, serious adverse events (SAEs [based on hospitalization or emergency room (ER) claim]), healthcare resource utilization (HCRU), and costs were evaluated descriptively, with Kaplan-Meier analysis for overall survival (OS).Results: Of 923 patients, 714 were in the ARPI cohort and 209 in the taxane cohort. Overall, 33.3% vs 53.6% of patients in the ARPI vs taxane cohorts received a subsequent treatment (p < 0.001), most commonly taxanes in both cohorts. Median OS was ≈1 year in both cohorts. SAEs were more frequent in the taxane cohort (66.0% vs 42.2%; p < 0.001). The taxane cohort had more ER, outpatient, and pharmacy visits (p < 0.0001), while the ARPI cohort had more hospitalizations (p < 0.0001).Conclusions: Results demonstrate that patients with mCRPC receiving common treatment sequences have suboptimal survival, frequent SAEs, and high HCRU and costs. Interpretation is limited by historical data and residual confounding.","PeriodicalId":12099,"journal":{"name":"Expert Review of Anticancer Therapy","volume":" ","pages":"1-11"},"PeriodicalIF":3.0,"publicationDate":"2026-10-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149106232","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Targeting cancer stem cells with ribosome-inactivating proteins: from molecular mechanisms to clinical translation. 用核糖体失活蛋白靶向癌症干细胞：从分子机制到临床翻译。

IF 3 3区医学

Expert Review of Anticancer Therapy Pub Date : 2026-10-02 DOI: 10.1080/14737140.2026.2738622

Aishwarya Rai, Alma Vikram, Tej Pal Singh, Pradeep Sharma, Sujata Sharma

{"title":"Targeting cancer stem cells with ribosome-inactivating proteins: from molecular mechanisms to clinical translation.","authors":"Aishwarya Rai, Alma Vikram, Tej Pal Singh, Pradeep Sharma, Sujata Sharma","doi":"10.1080/14737140.2026.2738622","DOIUrl":"10.1080/14737140.2026.2738622","url":null,"abstract":"Introduction: Cancer stem cells (CSCs) are a rare but highly tumorigenic subpopulation that drives tumor initiation, therapeutic resistance, metastasis, and disease recurrence. Their intrinsic resistance to conventional therapies has prompted the development of targeted strategies capable of selectively eliminating CSCs while sparing normal cells and tissues.Areas covered: This review summarizes the current understanding of ribosome-inactivating proteins (RIPs) as targeted therapeutics against CSCs. We discuss the structural and mechanistic features of RIPs, their ability to induce apoptosis and disrupt CSC-associated signaling pathways, and recent advances in RIP-based delivery platforms, including immunotoxins, ligand-directed conjugates, recombinant fusion proteins, and nanocarriers. Relevant literature was identified through comprehensive searches of PubMed, Scopus, and Web of Science, focusing on studies investigating RIPs in cancer biology, targeted therapy, and CSC-directed treatment.Expert opinion: RIPs represent a promising class of biologics for CSC targeted therapy owing to their potent cytotoxic activity and versatility in targeted delivery systems. However, challenges including immunogenicity, systemic toxicity, intracellular delivery, and limited clinical translation remain significant barriers. Future advances in protein engineering and precision delivery technologies are expected to improve the therapeutic index of RIP‑based agents and accelerate their translation into clinically effective anticancer therapies.","PeriodicalId":12099,"journal":{"name":"Expert Review of Anticancer Therapy","volume":" ","pages":"1-17"},"PeriodicalIF":3.0,"publicationDate":"2026-10-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149030070","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

A nephrology perspective on the clinical impact and management of delayed high-dose methotrexate elimination. 延迟大剂量甲氨蝶呤消除的临床影响和管理的肾脏学观点。

IF 3 3区医学

Expert Review of Anticancer Therapy Pub Date : 2026-10-01 Epub Date: 2026-05-27 DOI: 10.1080/14737140.2026.2677940

María José Soler, Laura Cosmai, Lui Forni, Jolanta Małyszko, Rukshana Shroff, Ben Sprangers, Corinne Isnard Bagnis

{"title":"A nephrology perspective on the clinical impact and management of delayed high-dose methotrexate elimination.","authors":"María José Soler, Laura Cosmai, Lui Forni, Jolanta Małyszko, Rukshana Shroff, Ben Sprangers, Corinne Isnard Bagnis","doi":"10.1080/14737140.2026.2677940","DOIUrl":"10.1080/14737140.2026.2677940","url":null,"abstract":"Introduction: Delayed methotrexate elimination (DME) is observed in ~15% of treatment cycles in patients with cancer receiving high-dose methotrexate (HDMTX). Given the strong association between DME and nephrotoxicity, oncologists might benefit from the input of a nephrologist/medical oncologist with a focus on nephrology when assessing and planning treatment for patients requiring HDMTX.Areas covered: Identifying patients who are at risk of DME and related acute kidney injury (AKI), and developing a bespoke assessment and monitoring plan (with a focus on kidney assessment and monitoring), may help to reduce the risk of complications and enable the continuation of HDMTX treatment, hopefully optimizing long-term survival outcomes.Expert opinion: In this perspective article, based on a search of PubMed literature and expert opinion, we explore the definition and causes of DME and AKI, and the impact of these on patients receiving HDMTX, and examine the key risk factors and early indicators of DME and AKI. A pathway with a nephrology focus is suggested for the assessment, monitoring, and treatment of patients with or at risk of DME.","PeriodicalId":12099,"journal":{"name":"Expert Review of Anticancer Therapy","volume":" ","pages":"1285-1291"},"PeriodicalIF":3.0,"publicationDate":"2026-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148028760","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Emerging immune checkpoint inhibitor strategies in cervical cancer: a scoping review of ongoing clinical trials. 宫颈癌中新出现的免疫检查点抑制剂策略：正在进行的临床试验的范围审查。

IF 3 3区医学

Expert Review of Anticancer Therapy Pub Date : 2026-10-01 Epub Date: 2026-05-22 DOI: 10.1080/14737140.2026.2677932

Karolina Górniak, Radosław Łupkowski, Mirosława Püsküllüoglu, Paweł Blecharz, Renata Pacholczak-Madej

{"title":"Emerging immune checkpoint inhibitor strategies in cervical cancer: a scoping review of ongoing clinical trials.","authors":"Karolina Górniak, Radosław Łupkowski, Mirosława Püsküllüoglu, Paweł Blecharz, Renata Pacholczak-Madej","doi":"10.1080/14737140.2026.2677932","DOIUrl":"10.1080/14737140.2026.2677932","url":null,"abstract":"Introduction: Immunotherapy with immune checkpoint inhibitors (ICIs) has become an important component of cervical cancer treatment, leading to improved outcomes in selected patient populations. However, despite recent approvals, prognosis in recurrent or metastatic disease remains poor and the immunotherapy landscape is rapidly evolving with the development of novel agents and combination strategies.Areas covered: This scoping review maps emerging ICI-based strategies in cervical cancer, focusing on novel targets, next-generation programmed cell death protein 1/programmed death-ligand 1 (PD-1/PD-L1) antibodies, bispecific antibodies and combination regimens. Ongoing phase I-II interventional clinical trials were identified through ClinicalTrials.gov and the European Union Clinical Trials Register from database inception to 1 February 2026. Fifty-nine clinical trials were included in the analysis. Evidence was synthesized descriptively and organized thematically. The final protocol was registered in the Open Science Framework (https://osf.io/swdz9/overview).Expert opinion: The expanding role of ICIs across multiple disease stages suggests that most patients with cervical cancer will be exposed to ICIs during their treatment course. However, widespread clinical implementation is limited by a lack of validated predictive biomarkers, cost considerations and toxicity management. Future progress will depend on biomarker-driven trial designs, rational combination strategies and studies addressing optimal sequencing and immunotherapy rechallenge.","PeriodicalId":12099,"journal":{"name":"Expert Review of Anticancer Therapy","volume":" ","pages":"1375-1385"},"PeriodicalIF":3.0,"publicationDate":"2026-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147971343","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Predictors of warfarin therapeutic dose in cancer patients: a preliminary comparative study using machine learning-integrated explainable artificial intelligence and Bayesian models. 癌症患者华法林治疗剂量的预测因素：使用机器学习集成可解释人工智能和贝叶斯模型的初步比较研究。

IF 3 3区医学

Expert Review of Anticancer Therapy Pub Date : 2026-10-01 Epub Date: 2026-06-02 DOI: 10.1080/14737140.2026.2682871

Kannan Sridharan, Gowri Sivaramakrishnan, Matteo Santoni

{"title":"Predictors of warfarin therapeutic dose in cancer patients: a preliminary comparative study using machine learning-integrated explainable artificial intelligence and Bayesian models.","authors":"Kannan Sridharan, Gowri Sivaramakrishnan, Matteo Santoni","doi":"10.1080/14737140.2026.2682871","DOIUrl":"10.1080/14737140.2026.2682871","url":null,"abstract":"Background: Warfarin dosing in cancer patients is challenging due to altered pathophysiology and variable responses. While machine learning offers predictive potential, clinical adoption requires interpretability. This study is an initial attempt at addressing whether different dosing strategies are required in this vulnerable population.Research design and methods: This observational study analyzed 1,746 patients (124 with cancer) from the International Warfarin Pharmacogenetics Consortium database. Five machine learning algorithms were developed and compared with the best-performing model interpreted using SHAP analysis. Bayesian Additive Regression Trees provided uncertainty quantification, and the Virtual Twins method estimated cancer's individualized treatment effect on dose requirements.Results: Genetic variants, particularly VKORC1 and CYP2C9, dominated dose prediction in both cohorts. However, cancer introduced complexity: clinical predictors showed greater variability and prediction errors, while Bayesian analysis revealed wider uncertainty intervals for inaccurate estimates. The Virtual Twins method demonstrated substantial heterogeneity in cancer's effect, with mean individualized treatment effect of 3.35 mg/week, yet 62.5% of patients exhibited positive effects indicating higher dose requirements. These findings suggest uniform dose adjustments for cancer patients may be inappropriate.Conclusions: Cancer patients possibly require personalized warfarin dosing, as genetic and clinical factors interact unpredictably. Explainable artificial intelligence and Bayesian models potentially enable individualized anticoagulation in oncology.","PeriodicalId":12099,"journal":{"name":"Expert Review of Anticancer Therapy","volume":" ","pages":"1387-1399"},"PeriodicalIF":3.0,"publicationDate":"2026-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148053456","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Cell-free DNA in prostate cancer and treatment selection. 无细胞DNA在前列腺癌中的作用及治疗选择。

IF 3 3区医学

Expert Review of Anticancer Therapy Pub Date : 2026-10-01 Epub Date: 2026-06-14 DOI: 10.1080/14737140.2026.2688295

Kate McKendry, Corinne Maurice-Dror, Kim N Chi

{"title":"Cell-free DNA in prostate cancer and treatment selection.","authors":"Kate McKendry, Corinne Maurice-Dror, Kim N Chi","doi":"10.1080/14737140.2026.2688295","DOIUrl":"10.1080/14737140.2026.2688295","url":null,"abstract":"Introduction: Metastatic prostate cancer is a leading cause of global cancer-related mortality. Contemporary treatment strategies are increasingly guided by genomic analyses, which are typically performed on archival or newly obtained biopsies. Nevertheless, tissue biopsies in this context face significant technical and clinical challenges. Circulating tumor DNA (ctDNA) testing from peripheral blood is a promising approach that addresses many of these limitations and enables sequential testing.Areas covered: This review examines the evidence for ctDNA in prostate cancer management and considers where it may be most effectively integrated into clinical practice. We discuss the strengths and limitations of ctDNA-based diagnostics, the key principles guiding clinical interpretation, and future directions, including novel applications under development in clinical trials.Expert opinion: In the metastatic castration-resistant prostate cancer (mCRPC) setting, ctDNA genomic profiling is an established method to identify patients eligible for PARP inhibitor therapy, and an emerging biomarker for prognostication, treatment selection, and response assessment. The results of ongoing clinical trials will inform on the future role of ctDNA for prostate cancer.","PeriodicalId":12099,"journal":{"name":"Expert Review of Anticancer Therapy","volume":" ","pages":"1357-1374"},"PeriodicalIF":3.0,"publicationDate":"2026-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148217265","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0